viewArix Bioscience PLC

Arix Bioscience confirms Autolus to launch proposed public offering

The final price has not yet been set but Autolus is planning on issuing up to 4.6mln American Depositary Shares (ADS) as part of the offering

Autolus was spun out from University College London in 2014

Biotech investor Arix Bioscience PLC (LON:ARIX) has confirmed that its investee company, Autolus Therapeutics PLC (NASDAQ:AUTL), has announced the launch of a proposed public offering in the United States.

The proposed maximum aggregate offering amount specified in the filing is 4mln American Depositary Shares (ADS), which does not include the underwriters’ option to purchase 600,000 additional ADS.

Each ADS represents one ordinary share. The final price per ADS in the offering will be determined following a book building process.

Arix shares were unchanged on Tuesday at 143p.

Quick facts: Arix Bioscience PLC

Price: 88.28 GBX

Market: LSE
Market Cap: £119.67 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...



Arix Bioscience 'building a very exciting, diversified healthcare company'

Dr Joe Anderson, chief executive of Arix Bioscience Plc (LON:ARIX) runs Proactive Investors through the company's strategy and outlook. ''We're focused on the innovation end of healthcare, which is exactly where we believe the value is in healthcare today'', Anderson says.

on 19/5/17

2 min read